

FORM PTO-144	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: AL01019	SERIAL NO.: 09/955,383
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: ASLANIAN	
(Use several sheets if necessary)		FILING DATE: Sept. 18, 2001	GROUP: 1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
H.C.	AA	4,767,778	8/88	U.S. PATENT	514	397	
H.C.	AB	5,352,707	10/94	U.S. PATENT	514	397	
H.C.	AC	5,869,479	2/99	U.S. PATENT	514	397	
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
H.C.	AG	WO 93/01812	2/93	INTERNATIONAL PATENT				
H.C.	AH	WO 93/12093	6/93	INTERNATIONAL PATENT				
H.C.	AI	WO 95/14007	5/95	INTERNATIONAL PATENT				
H.C.	AJ	WO 98/58646	12/98	INTERNATIONAL PATENT				
H.C.	AK	WO 96/29315	9/96	INTERNATIONAL PATENT				
H.C.	AL	EU 0448 765 B1	3/90	EUROPEAN PATENT				
H.C.	AM	EU 0 420 396 B1	7/90	EUROPEAN PATENT				
	AN							
	AO							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

H.C.	AP	Howson, Bioorganic & Medicinal Chemistry Letters, Two Novel, Potent and Selective Histamine H3 Receptor Agonists, Vol. 2, pp. 77-78, 1992.
H.C.	AQ	Stark, J. Med. Chem. , Novel Carbamates as Potent Histamine H3 Receptor Antagonists with High in Vitro and Oral In Vivo Activity, 39, pp. 1157-1163.
H.C.	AR	Sasse, Bioorganic & Medicinal Chemistry , (Partial) Agonist/Antagonist Properties of Novel Diarylalkyl, Vol 8 (2000) pp. 1139-1149.
H.C.	AS	Bagley, J. Med. Chem. 1991, New 1-(Heterocyclalkyl)-4-(Propionanilido)-4-Piperidinyl, 34, pp 827-941.
H.C.	AT	Huls, Bioorganic & Medicinal Chemistry Letters, Diphenylmethyl Ethers: Synthesis and Histamine, Vol. 6, No. 16, pp. 2013-2018, 1996.
H.C.	AU	Buschauer, J. Med. Chem. 1989, Synthesis and in Vitro Pharmacology of Arpromidine, 32, pp 1963-1970, 1989.
H.C.		Schulze, Arch. Pharm. (Weinheim), Synthese und kombinierte H1/H2-antagonistische, Vol. 327, pp. 455-462, 1994. -
H.C.	AV	Schulze, European Journal of Pharmaceutical Sciences, Combined histamine H1/H2 receptor antagonists, Vol 6, pp. 177-186, 1998.
H.C.	AW	van der Goot, Eur J. Med. Chem. , Isothiourea analogues of histamine as potent agonists, Vol 27, pp. 511-517, 1992.
H.C.	AX	Walczynski, Il Farmaco, Non-imidazole histamine H3 ligands, Vo. 54, pp. 684-694, 1999.
H.C.	AY	Brown, Br. J. Pharmac. , Pharmacological studies with SK & F 93944, Vol. 87, pp. 569-578, 1986.
H.C.	AZ	West, Molecular Pharmacology, Identificatin of Two H3-Histamine Receptor Subtypes, Vol. 38, pp. 610-613, 1990.
H.C.	BA	Clapham, Brit. J. Pharm. Suppl. , Ability of the Selective Histamine H3 Receptor Antagonist, Vol. 110, pp. Abs. 65P, 00/00, 1993.
H.C.	BB	Yokoyama, European Journal of Pharmacology, Effect of Thioperamide, Vol. 234, pp 129-133, 1993.
H.C.	BC	Schlicker, Br. J. Pharmacol., Novel Histamine H3 Receptor Antagonists, Vol. 112, pp. 1043-1048, 1994.
H.C.	BD	Leurs, Progre. Drug. Res. , The Histamine H3-Receptor, Vol. 39, pp. 127-165, 00/00, 1992.



H.C.	BE	Lipid Histamine Receptor, Pharmacochimistry of H3-Receptors, pp. 57-72, 00/00, 1992.
/4-L.	BF	Stand European Journal of Pharmaceutical Sciences, New potent Histamine H3-Receptor Vol 3, pp. 95-104, 1995
	BG	
EXAMINER	DATE CONSIDERED	
<i>Henry Liu</i>	<i>3/10/03</i>	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

RECEIVED  
FEB 20 2002  
TECH CENTER 1600/2900